

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8177482

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
HAMILTON SA LLC	09/18/2023

RECEIVING PARTY DATA

Name:	HELSINN HEALTHCARE SA
Street Address:	VIA PIAN SCAIROLO
City:	LUGANO
State/Country:	SWITZERLAND
Name:	HELSINN THERAPEUTICS (U.S.), INC.
Street Address:	200 WOOD AVENUE SOUTH, SUITE 100
City:	ISELIN
State/Country:	NEW JERSEY
Postal Code:	08830
Name:	HELSINN BIREX PHARMACEUTICALS LIMITED
Street Address:	15 DAMASTOWN RD, MULHUDDART
City:	DUBLIN
State/Country:	IRELAND

PROPERTY NUMBERS Total: 74

Property Type	Number
Patent Number:	7947724
Patent Number:	7947725
Patent Number:	7960424
Patent Number:	8426450
Patent Number:	8518981
Patent Number:	8598218
Patent Number:	8598219
Patent Number:	8623826
Patent Number:	8658797
Patent Number:	8729094
Patent Number:	8951969
Patent Number:	9066980

PATENT

Property Type	Number
Patent Number:	9125905
Patent Number:	9173942
Patent Number:	9186357
Patent Number:	9271975
Patent Number:	9308266
Patent Number:	9403772
Patent Number:	9403867
Patent Number:	9439854
Patent Number:	9457020
Patent Number:	9457021
Patent Number:	9546157
Patent Number:	9675600
Patent Number:	9751836
Patent Number:	9872883
Patent Number:	9908907
Patent Number:	9926337
Patent Number:	9943515
Patent Number:	9951016
Patent Number:	9956261
Patent Number:	9975921
Patent Number:	9981002
Patent Number:	10005803
Patent Number:	10208073
Patent Number:	10233154
Patent Number:	10278964
Patent Number:	10300105
Patent Number:	10407390
Patent Number:	10501479
Patent Number:	10576122
Patent Number:	10577384
Patent Number:	10624911
Patent Number:	10676440
Patent Number:	10828297
Patent Number:	10905737
Patent Number:	11299472
Application Number:	16817683
Application Number:	17688016
Patent Number:	10717721

Property Type	Number
Patent Number:	10894041
Patent Number:	10961195
Patent Number:	11312698
Application Number:	17119482
Application Number:	17075757
Application Number:	17185206
Application Number:	17634616
Patent Number:	7825138
Patent Number:	8466173
Patent Number:	8895586
Patent Number:	8450375
Patent Number:	8501817
Patent Number:	7838564
Patent Number:	8501818
Patent Number:	8501819
Patent Number:	8664278
Application Number:	63212148
Application Number:	17838308
Application Number:	63245270
Application Number:	16982107
Application Number:	17986934
Application Number:	17699522
Patent Number:	9382191
Application Number:	15804804

CORRESPONDENCE DATA

Fax Number: (415)693-2222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000

Email: crhem@cooley.com

Correspondent Name: COOLEY LLP

Address Line 1: 3 EMBARCADERO CENTER, 20TH FLOOR

Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	324998-125
NAME OF SUBMITTER:	C. RHEM
SIGNATURE:	/CR/
DATE SIGNED:	09/20/2023

Total Attachments: 10

source=Oberland - Helsinn - Patent Security Release Executed#page1.tif
source=Oberland - Helsinn - Patent Security Release Executed#page2.tif
source=Oberland - Helsinn - Patent Security Release Executed#page3.tif
source=Oberland - Helsinn - Patent Security Release Executed#page4.tif
source=Oberland - Helsinn - Patent Security Release Executed#page5.tif
source=Oberland - Helsinn - Patent Security Release Executed#page6.tif
source=Oberland - Helsinn - Patent Security Release Executed#page7.tif
source=Oberland - Helsinn - Patent Security Release Executed#page8.tif
source=Oberland - Helsinn - Patent Security Release Executed#page9.tif
source=Oberland - Helsinn - Patent Security Release Executed#page10.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This Release of Security Interest in Intellectual Property (this “**Release**”) is made as of September 18, 2023, by HAMILTON SA LLC, a Delaware limited liability company, as collateral agent (“**Agent**”), in favor of HELSINN HEALTHCARE SA, a corporation (*Aktiengesellschaft*) incorporated and organized under the laws of Switzerland (“**Helsinn Healthcare**”), HELSINN THERAPEUTICS (U.S.), INC., a Delaware corporation (“**Helsinn Therapeutics**”), and HELSINN BIREX PHARMACEUTICALS LIMITED, a private limited company organized under the laws of Ireland (together with Helsinn Healthcare and Helsinn Therapeutics, each a “**Grantor**” and, collectively, the “**Grantors**”).

Recitals

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of December 30, 2022 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**Patent Security Agreement**”), recorded with the U.S. Patent and Trademark Office on December 30, 2022, at Reel/Frame No. 062254/0888 (Patents), the Grantors granted and pledged to Agent a security interest in all of the Grantors’ right, title and interest in, to and under the Grantors’ patents (including without limitation those patents described on Exhibit A hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements all rights corresponding thereto throughout the world and all re-issues, divisions, continuations, renewals, extensions and continuations-in-part thereof (collectively, the “**Intellectual Property Collateral**”).

WHEREAS, the Grantors have requested and Agent has agreed to release its security interest in and to the Intellectual Property Collateral and terminate the Patent Security Agreement.

Agreement

Now, therefore, Agent terminates and releases all of its right, title and interest in, to and under the Intellectual Property Collateral and terminates the Patent Security Agreement, and reassigns to the Grantors all right, title, and interest of Agent in or to the Intellectual Property Collateral.

Agent hereby authorizes the Grantors or the Grantors’ authorized representative to (i) record this Release with the U.S. Patent and Trademark Office, and/or (ii) otherwise record or file this Release in the applicable governmental office or agency.

[SIGNATURE PAGE FOLLOWS]

AGENT:

HAMILTON SA LLC

By: David Dubinsky

Name: David Dubinsky

Title: Authorized Signatory

Address of Agent:

c/o Oberland Capital Management LLC
1700 Broadway, 37th Floor
New York, NY 10019

Exhibit A - Patents

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
Liquid pharmaceutical formulations of palonosetron	US	11/186311	07/21/2005	NONE	7947724	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	11/388268	05/24/2011	NONE	7947725	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	11/388270	06/14/2011	NONE	7960424	Helsinn Healthcare S.A.
Substituted 4-phenyl pyridines having anti-emetic effect	US	13/478361	05/23/2012	NONE	8426450	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/087012	08/27/2013	NONE	8518981	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/901288	05/23/2013	NONE	8598218	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/901437	05/23/2013	NONE	8598219	Helsinn Healthcare S.A.
Compositions and methods for treating centrally mediated nausea and vomiting	US	13/077462	03/31/2011	NONE	8623826	Helsinn Healthcare S.A.
Asymmetric ureas and medical uses thereof	US	13/404165	02/24/2012	NONE	8658797	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/902132	05/24/2013	NONE	8729094	Helsinn Healthcare S.A.
Compositions and methods for treating centrally mediated nausea and vomiting	US	14/069885	03/31/2011	NONE	8951969	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/902299	05/24/2013	NONE	9066980	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	14/597489	09/08/2015	NONE	9125905	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	13/901830	05/24/2013	NONE	9173942	Helsinn Healthcare S.A.

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
formulations of palonosetron						
Compositions and methods for treating centrally mediated nausea and vomiting	US	14/069927	03/31/2011	NONE	9186357	Helsinn Healthcare S.A.
Compositions and methods for treating centrally mediated nausea and vomiting	US	14/069970	03/31/2011	NONE	9271975	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	14/070981	11/04/2013	NONE	9308266	Helsinn Healthcare S.A.
4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-(phosphonoxy)methyl)piperazin-1-ium as a neurokinin receptor modulator	US	14/360991	11/28/2012	NONE	9403772	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	14/539318	04/18/2013	NONE	9403867	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	14/793233	07/07/2015	NONE	9439854	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	14/855564	10/04/2016	NONE	9457020	Helsinn Healthcare S.A.
Liquid pharmaceutical formulations of palonosetron	US	15/190019	07/07/2015	NONE	9457021	Helsinn Healthcare S.A.
Asymmetric piperidinylsubstituted ureas as medicines	US	14/640551	03/06/2015	NONE	9546157	Helsinn Healthcare S.A.
Medical treatments based on anamorelin	US	14/839038	08/28/2015	NONE	9675600	Helsinn Healthcare S.A.

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
Asymmetric ureas and medical uses thereof	US	14/150360	02/24/2012	NONE	9751836	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	15/135147	04/18/2013	NONE	9872883	Helsinn Healthcare S.A.
Substituted piperaziniums for the treatment of emesis	US	15/194984	11/28/2012	NONE	9908907	Helsinn Healthcare S.A.
Substituted asymmetric ureas as modulators of ghrelin receptor activity	US	15/368362	03/06/2015	NONE	9926337	Helsinn Healthcare S.A.
Compositions and methods for treating centrally mediated nausea and vomiting	US	15/003327	03/31/2011	NONE	9943515	Helsinn Healthcare S.A.
Crystalline forms of an NK-1 antagonist	US	14/865370	09/25/2015	NONE	9951016	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	15/135107	04/18/2013	NONE	9956261	Helsinn Healthcare S.A.
Crystal forms of anamorelin	US	14/927669	06/17/2013	NONE	9975921	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	15/135051	04/18/2013	NONE	9981002	Helsinn Healthcare S.A.
Crystalline forms of fosnetupitant	US	15/282016	09/30/2016	NONE	10005803	Helsinn Healthcare S.A.
Substituted 4-Phenyl-Pyridines for the Treatment of NK-1 Receptor Related Diseases	US	15/874325	11/28/2012	NONE	10208073	Helsinn Healthcare S.A.
Crystalline forms of an NK-1 antagonist	US	15/918868	09/25/2015	NONE	10233154	Helsinn Healthcare S.A.
Medical treatments based on anamorelin	US	15/590025	08/28/2015	NONE	10278964	Helsinn Healthcare S.A.

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
Methods of producing anamorelin hydrochloride having controlled chloride content	US	15/963284	04/18/2013	NONE	10300105	Helsinn Healthcare S.A.
Asymmetric ureas and medical uses thereof	US	15/663761	02/24/2012	NONE	10407390	Helsinn Healthcare S.A.
Benzenesulfonyl-asymmetric ureas and medical uses thereof	US	15/464430	03/21/2017	NONE	10501479	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	16/383623	04/18/2013	NONE	10576122	Helsinn Healthcare S.A.
Substituted asymmetric ureas as modulators of ghrelin receptor activity	US	15/889589	03/06/2015	NONE	10577384	Helsinn Healthcare S.A.
Physiologically balanced injectable formulations of fosnetupitant	US	15/611785	06/02/2017	NONE	10624911	Helsinn Healthcare S.A.
Crystalline forms of an NK-1 antagonist	US	16/259913	09/25/2015	NONE	10676440	Helsinn Healthcare S.A.
Compositions and methods for treating centrally mediated nausea and vomiting	US	15/923050	03/31/2011	NONE	10828297	Helsinn Healthcare S.A.
Methods of producing anamorelin hydrochloride having controlled chloride content	US	16/751836	04/18/2013	NONE	10905737	Helsinn Healthcare S.A.
Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof	US	16/767842	12/07/2018	NONE	11299472	Helsinn Healthcare S.A.

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT	US	16/817683	06/02/2017	20200206249	Pending	Helsinn Healthcare S.A.
Fumarate Salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, Methods of Preparation, and Uses Thereof	US	17/688016	03/07/2022	20220340541	Pending	Helsinn Healthcare S.A.
Substituted 4-Phenyl-Pyridines for the Treatment of NK-1 Receptor Related Diseases	US	16/228835	11/28/2012	NONE	10717721	Helsinn Healthcare S.A.
Medical treatments based on anamorelin	US	16/275669	08/28/2015	NONE	10894041	Helsinn Healthcare S.A.
Crystalline forms of an NK-1 antagonist	US	16/863038	09/25/2015	NONE	10961195	Helsinn Healthcare S.A.
Substitute 4-Phenyl-Pyridines for the Treatment of NK-1 Receptor Related Diseases	US	16/896135	11/28/2012	NONE	11312698	Helsinn Healthcare S.A.
MEDICAL TREATMENTS BASED ON ANAMORELIN	US	17/119482	08/28/2015	20210093627	Pending	Helsinn Healthcare S.A.
COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING	US	17/075757	03/31/2011	20210100794	Pending	Helsinn Healthcare S.A.
CRYSTALLINE FORMS OF NK-1 ANTAGONIST	US	17/185206	09/25/2015	20210269401	Pending	Helsinn Healthcare S.A.
METHODS OF	US	17/634616	08/28/2020	20220323430	Pending	Helsinn Healthcare S.A.

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
MANUFACTURING ANAMORELIN TABLETS HAVING IMPROVED STABILITY						
CRYSTAL FORMS OF (3R)-1-(2-METHYLALANYL-DTRYPTOPHYL)-3-(PHENYLMETHYL)-3-PIPERIDINECARBOXYLIC ACID 1,2,2-TRIMETHYLHYDRAZIDE	US	11/165598	06/22/2005	20070004638	7825138	Helsinn Healthcare S.A.
CRYSTAL FORMS OF (3R)-1-(2-METHYLALANYL-DTRYPTOPHYL)-3-(PHENYLMETHYL)-3-PIPERIDINECARBOXYLIC ACID 1,2,2-TRIMETHYLHYDRAZIDE	US	12/831009	07/06/2010	20110003996	8466173	Helsinn Healthcare S.A.
Substituted 4-Phenyl-Pyridines for the Treatment of NK-1 Receptor Related Diseases	US	13/864381	05/23/2012	20130231315	8895586	Helsinn Healthcare S.A.
STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS	US	11/908531	03/14/2006	20080194699	8450375	HEL SINN BIREX PHARMACEUTICALS LIMITED

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
AND METHODS OF USING THEREOF						
STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME	US	12/401812	03/11/2009	20100029783	8501817	HEL SINN BIREX PHARMACEUTICALS LIMITED
STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF	US	12/549258	03/07/2006	20100041767	7838564	HEL SINN BIREX PHARMACEUTICALS LIMITED
STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME	US	12/687605	01/14/2010	20100152300	8501818	HEL SINN BIREX PHARMACEUTICALS LIMITED
STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF	US	12/948593	11/17/2010	20110065803	8501819	HEL SINN BIREX PHARMACEUTICALS LIMITED
STABILIZED COMPOSITIONS OF	US	13/735710	03/14/2006	20130310461	8664278	HEL SINN BIREX PHARMACEUTICALS

Official Title	Country	Application No	Filing Date	Publication No	Registration No	Ownership
VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF						LIMITED
Use of Anamorelin to treat Cancer-Related Fatigue	US	63/212148	06/18/2021	NONE	Pending	Helsinn Healthcare S.A.
Use of Anamorelin to treat Cancer-Related Fatigue	US	17/838308	06/13/2022	NONE	Pending	Helsinn Healthcare S.A.
Methods of Determining and Providing Clinically Meaningful Improvements on Patient Outcomes in Anorexia/Cachexia Patients	US	63/245270	09/17/2021	NONE	Pending	Helsinn Healthcare S.A.
New Centrally-Active Ghrelin Agonist and Medical Uses Thereof	US	16/982107	03/14/2019	NONE	Pending	Helsinn Healthcare S.A.
Physiologically Balanced Injectable Formulation of Fosnetupitant	US	17/986,934	11/15/2022	NONE	Pending	Helsinn Healthcare S.A.
Substitutes 4-Phenyl-Pyridines for the Treatment of NK-1 Receptor Related Diseases	US	17/699522	03/21/2022	NONE	Pending	Helsinn Healthcare S.A.
Stabilized Compositions of Volatile Alkylating Agents & Method of Using Thereof	US	14/153914	01/13/2014	NONE	9382191	Helsinn Healthcare S.A.
Methods for Treating Skin Disorders with a Topical Composition of bis-(2-Chloroethy) Methylamine	US	15/804804	11/06/22017	NONE	Pending	Helsinn Birex Pharmaceuticals Ltd.